Patents Assigned to Pfizer Inc.
  • Publication number: 20220193063
    Abstract: The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: Pfizer Inc.
    Inventors: Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar
  • Patent number: 11364303
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise an engineered cysteine for site-specific conjugation.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 21, 2022
    Assignee: Pfizer Inc.
    Inventors: Madan Katragadda, Russell Dushin, Lawrence Nathan Tumey
  • Patent number: 11365263
    Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 21, 2022
    Assignee: PFIZER INC.
    Inventors: Andreas Maderna, Chakrapani Subramanyam, Lawrence N. Tumey, Zecheng Chen, Jeffrey M. Casavant
  • Patent number: 11365253
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 21, 2022
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Eric M. Bennett, Nathan Higginson-Scott, Huilan Gao, Zong Sean Juo, Stefano V. Gulla, Christine Huard, Sreekumar R. Kodangattil, Jian Li, Weining Lu, Xueping Fan, David J. Salant
  • Publication number: 20220184041
    Abstract: This application includes a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein the variables R1a, R1b, R2, R3, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I and methods of treatment comprising administering to a patient in need thereof a compound of Formula I for the treatment of transthyretin amyloidosis and diseases related thereto.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: Pfizer Inc.
    Inventors: Shawn Cabral, Daniel Paul Canterbury, Robert Lee Dow, Andrew Fensome, Magdalena Korczynska, Sophie Yvette Lavergne, Allyn Timothy Londregan, Vincent Mascitti, David Walter Piotrowski, Andre Shavnya, Meihua Mike Tu, Tao Wang, Hanna Maria Wisniewska
  • Patent number: 11359024
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: June 14, 2022
    Assignees: PFIZER INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akhurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
  • Patent number: 11351149
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 7, 2022
    Assignee: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • Publication number: 20220168293
    Abstract: This invention relates to a method of managing an adverse event in a renal cell carcinoma (RCC) patient undergoing treatment with axitinib, or a pharmaceutically acceptable salt thereof, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 1-7 days to allow the adverse event to resolve before restarting treatment. Additionally, the invention relates to a method of managing an adverse event in an RCC patient undergoing treatment with a combination of axitinib, or a pharmaceutically acceptable salt thereof, and an immune-oncology (IO) agent, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 4-11 days to allow the adverse event to resolve before restarting axitinib, or a pharmaceutically acceptable salt thereof, treatment.
    Type: Application
    Filed: November 30, 2021
    Publication date: June 2, 2022
    Applicant: PFIZER INC.
    Inventor: Despoina Thomaidou
  • Publication number: 20220168410
    Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Applicant: Pfizer Inc.
    Inventors: Robert G.K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
  • Patent number: 11339159
    Abstract: The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: May 24, 2022
    Assignee: Pfizer Inc.
    Inventors: Omar Ahmad, Andrew Fensome, Erik Alphie LaChapelle, Ethan Lawrence Fisher, Rayomand J. Unwalla, Jun Xiao, Lei Zhang
  • Publication number: 20220152181
    Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.
    Type: Application
    Filed: October 25, 2021
    Publication date: May 19, 2022
    Applicant: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Laurent Oliver Chorro, Robert George Konrad Donald, Jacqueline Marie Lypowy, Rosalind Pan
  • Publication number: 20220142927
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Applicant: PFIZER INC.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Publication number: 20220142976
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Application
    Filed: December 17, 2021
    Publication date: May 12, 2022
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • Publication number: 20220144846
    Abstract: The present invention discloses a novel crystalline form of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone free base, pharmaceutical composition containing the same, preparations thereof and uses thereof.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 12, 2022
    Applicant: Pfizer Inc.
    Inventors: Xiaojing YANG, Amanda Patrice Surajhie SAMUEL
  • Patent number: 11325909
    Abstract: The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or tri-hydrate; as well as polymorphs, pharmaceutical compositions, dosage forms, and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase (ACC) enzyme(s) in an animal.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: May 10, 2022
    Assignee: Pfizer Inc.
    Inventors: Dilinie Fernando, Shawn Marie LaCasse, Kristin Elizabeth Price Wiglesworth
  • Patent number: 11326185
    Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 10, 2022
    Assignees: LONZA BIOLOGICS PLC, PFIZER INC.
    Inventors: James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
  • Publication number: 20220136020
    Abstract: The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.
    Type: Application
    Filed: February 20, 2020
    Publication date: May 5, 2022
    Applicant: Pfizer Inc.
    Inventors: Ling Chu, Scott Andrew Cook, Nishith Merchant, Justin Keith Moran
  • Publication number: 20220125777
    Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.
    Type: Application
    Filed: January 31, 2020
    Publication date: April 28, 2022
    Applicant: Pfizer Inc.
    Inventors: Zhou Zhu, Yuan Liu
  • Publication number: 20220127262
    Abstract: The invention relates to a crystalline form of 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl) piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one (PF-06873600) free base (Form 1).
    Type: Application
    Filed: January 13, 2020
    Publication date: April 28, 2022
    Applicant: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Martha Alicia Ornelas
  • Publication number: 20220127274
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Application
    Filed: January 10, 2022
    Publication date: April 28, 2022
    Applicant: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane